United Therapeutics/$UTHR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
- Ticker
- $UTHR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,400
- Headquarters
- Silver Spring, United States
- Website
- www.unither.com
UTHR Metrics
BasicAdvanced
$25B
21.24
$27.95
0.56
-
Price and volume
Market cap
$25B
Beta
0.56
52-week high
$609.35
52-week low
$430.02
Average daily volume
842K
Financial strength
Current ratio
5.732
Quick ratio
4.891
Interest coverage (TTM)
117.06%
Profitability
EBITDA (TTM)
1,496.2
Gross margin (TTM)
86.14%
Net profit margin (TTM)
41.56%
Operating margin (TTM)
44.53%
Effective tax rate (TTM)
16.66%
Revenue per employee (TTM)
$2,250,000
Management effectiveness
Return on assets (TTM)
11.61%
Return on equity (TTM)
19.32%
Valuation
Price to earnings (TTM)
21.237
Price to revenue (TTM)
8.147
Price to book
3.96
Price to tangible book (TTM)
4.03
Price to free cash flow (TTM)
23.632
Free cash flow yield (TTM)
4.23%
Free cash flow per share (TTM)
25.115
Growth
Revenue change (TTM)
2.49%
Earnings per share change (TTM)
9.04%
3-year revenue growth (CAGR)
14.33%
10-year revenue growth (CAGR)
7.21%
3-year earnings per share growth (CAGR)
16.53%
10-year earnings per share growth (CAGR)
3.05%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
Analyst projections of the future price of United Therapeutics stock.
Bulls say / Bears say
Two Phase 3 studies found that nebulised Tyvaso slowed lung-function decline in idiopathic pulmonary fibrosis, and the FDA has accepted the application for review with a decision expected in April 2027. Approval would give United Therapeutics a route into a new market. (Business Wire, United Therapeutics)
United Therapeutics has filed ralinepag’s application for PAH after positive ADVANCE OUTCOMES results. This new oral candidate could broaden growth beyond its established treprostinil-based products. (SEC, The Motley Fool)
A settlement with Liquidia removes Yutrepia’s PH-ILD indication and resolves several disputes, while providing United Therapeutics with about $320 million in net payments. That may strengthen Tyvaso’s position in PH-ILD and reduce the distraction of prolonged litigation. (SEC, Liquidia Corporation)
The existing business is under pressure: second-quarter revenue fell 2% year on year, with total Tyvaso sales down 4% and nebulised Tyvaso down 18%. The company attributed declines across Tyvaso and Remodulin to competition. (SEC)
The Liquidia settlement does not remove Yutrepia from the PAH market. RBC sees limited near-term upside for Tyvaso and expects third-quarter franchise sales to be flat year on year, below consensus. (MT Newswires)
The growth outlook has become harder to underwrite: management said second-quarter revenue was below its expectations, did not update its 2026 revenue outlook and acknowledged that the path to its 2027 run-rate target had narrowed. That leaves more of the growth case resting on future launches and execution. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
Upcoming events
No upcoming events
UTHR News
AllArticlesVideos
Funds containing UTHR
AllUSDEURGBP
Fund name | Fund size | $UTHR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.61% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.61% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.74% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.74% |
SPDR MSCI World Health Care£HEAW | $708M | 0.25% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.